Edith Cardenas-Vargas

Edith Cardenas-Vargas

Auto-generated profile, based on publicly available information

Edith Cardenas-Vargas

A Molecular Medicine Laboratory , Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas , Zacatecas , Mexico

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2018 in Hypertension in Pregnancy
Verified
Journal Article
Closed access
Margarita L. Martinez-FierroMargarita L. Martinez-Fierro
Margarita L. Martinez-Fierro
CRClaudia Castruita-De La Rosa
Claudia Castruita-De La Rosa
IGIdalia Garza-Veloz
Idalia Garza-Veloz
RCRosa M Cardiel-Hernandez
Rosa M Cardiel-Hernandez
MEMarcela A Espinoza-Juarez
Marcela A Espinoza-Juarez
YOYolanda Ortiz-Castro
Yolanda Ortiz-Castro
Background: Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective: To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods: We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex ProTM Human Cancer Biomarker Panels 1 and 2. Results: The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups (p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8–29.8 times in the study population. Conclusion: The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered.

13 June 2017 in Journal of Obstetrics and Gynaecology
Verified
Journal Article
Closed access
IGIdalia Garza-Veloz
Idalia Garza-Veloz
CRClaudia Castruita-De la Rosa
Claudia Castruita-De la Rosa
YOYolanda Ortiz-Castro
Yolanda Ortiz-Castro
Virginia Flores-MoralesVirginia Flores-Morales
Virginia Flores-Morales
MCMaria E. Castañeda-Lopez
Maria E. Castañeda-Lopez
Margarita L. Martinez-FierroMargarita L. Martinez-Fierro
Margarita L. Martinez-Fierro
Despite the implementation of programmes to improve maternal health, maternal and foetal mortality rates still remain high. The presence of maternal distress and its association with the development of pregnancy hypertensive disorders is not well established. The aim of this study was to evaluate the association between maternal distress and the development of hypertensive disorders in pregnancy in a prospective cohort of 321 Mexican women. Symptoms of maternal distressing were evaluated at week 20th of gestation using the General Health Questionnaire. The presence of acute somatic symptoms, social dysfunction, anxiety and insomnia increased the odds of developing a pregnancy hypertensive disorder by 5.1–26.4 times in study population (p values < .05). Our results support the participation of maternal distress in the development of hypertensive disorders of pregnancy. The implementation of effective programmes prioritising risk factors during pregnancy including the presence of maternal distressing factors is recommended.

4 April 2019 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
CRClaudia Castruita-De la Rosa
Claudia Castruita-De la Rosa
IGIdalia Garza-Veloz
Idalia Garza-Veloz
Ivan Delgado-EncisoIvan Delgado-Enciso
Ivan Delgado-Enciso
JOJuan C. Olivas-Chavez
Juan C. Olivas-Chavez
ECEdith Cardenas-Vargas
Edith Cardenas-Vargas
Margarita L. Martinez-FierroMargarita L. Martinez-Fierro
Margarita L. Martinez-Fierro
Objective: To evaluate the usefulness of the serum concentration of nine matrix metalloproteinases (MMPs) as biomarkers of spontaneous abortion. Methods: A retrospective nested cohort case-control study was carried out in Zacatecas, Mexico. MMP-1-3, MMP-7-10, and MMP-12-13 were analyzed in serum from women who had spontaneous abortion of unknown causes (n = 7), who suffered abortions attributed to urinary tract infection (n = 7) and from those with healthy pregnancies without complications (controls; n = 20). Protein profiles were determined between 11 and 13 weeks of gestation (GW) using the Bio-Plex Pro Human MMP Panel. Differences in serum MMP concentrations between the study groups and their correlation with clinical findings were evaluated statistically. Results: There were differences in serum concentrations of MMP-9 between groups of spontaneous abortion of unknown cause (13.2 ± 7.5 ng/µl), abortion attributed to urinary tract infection (11.6 ± 5.8 ng/µl) and the controls (11.8 ± 16.5 ng/µl) (p = 0.022). Compared with controls, higher serum concentrations of MMP-8, MMP-9 and MMP-10 were observed in the group of spontaneous abortions of unknown causes (p value < 0.05). A negative correlation between MMP-8 and MMP-9 and urine density was also identified (r = −0.949 p value = 0.0167; and r = −0.947, p = 0.0167).